Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson's and Alzheimer's Patients See more here
Read More
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies See more here
Read More
Annovis Issued Patent for Method of Treating Parkinson's Disease and Other Lewy Body Diseases See more here
Read More
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer's Disease See more here
Read More
Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares See more here
Read More
Annovis Bio Announces Pricing of Initial Public Offering See more here
Read More
Annovis Appoints Jeffrey McGroarty Chief Financial Officer See more here
Read More
QR Pharma Adopts new Corporate Name: Annovis Bio Change reflects enhanced focus on neurodegenerative diseases See more here
Read More